Get the Stockscreener App
22.05
1.17%
-0.26
After Hours:
22.05
Apellis Pharmaceuticals Inc stock is traded at $22.05, with a volume of 1.34M.
It is down -1.17% in the last 24 hours and down -4.96% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$22.31
Open:
$22.23
24h Volume:
1.34M
Relative Volume:
0.47
Market Cap:
$2.79B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-10.86
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-2.26%
1M Performance:
-4.96%
6M Performance:
-7.74%
1Y Performance:
-22.66%
1-Day Range:
$21.72
$22.38
1-Week Range:
$21.71
$23.69
52-Week Range:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.05 | 2.82B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
(APLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Yahoo Finance
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC - MarketBeat
ING Groep NV Acquires 866,200 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Market Overview: Will Apellis Pharmaceuticals Inc outperform the market in YEARWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS) - simplywall.st
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions - Sahm
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors - Sahm
(APLS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Finviz
Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsShort Setup & Reliable Intraday Trade Alerts - mfd.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded to Hold at Barclays - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
J. Safra Sarasin Holding AG Sells 45,184 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Equal-Weight Rating from Barclays | APLS Stock News - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Barclays - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 56.89% Upside Potential - DirectorsTalk Interviews
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction - Yahoo Finance
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution - Sahm
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp. - MarketBeat
Value Recap: Is BAFN a strong growth stockGap Up & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Buybacks Report: Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Apellis upgraded at BofA on launch trajectory for kidney disease therapy - MSN
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Apellis Pharma CEO Francois sells $592k in shares By Investing.com - Investing.com Canada
Caroline Baumal Sells 2,797 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 7,832 Shares - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 2,064 Shares of Stock - MarketBeat
Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis stock surges after Sobi $300 million royalty deal - MSN
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - ChartMill
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com Nigeria
Apellis Pharma CMO Baumal sells $37k in shares By Investing.com - Investing.com India
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock By Investing.com - Investing.com South Africa
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 2,892 Shares of Stock - MarketBeat
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033 - Intellectia AI
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):